PATENT CLAIM ANALYSIS

Application Number: 15933739
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "04400A"]

Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.

Claim (Index 27):
The compound of  claim 11 , comprising a modified oligonucleotide 16 linked nucleosides in length having a nucleobase sequence consisting of any one of SEQ ID NOs: 1016, 1528, 763, 1071, 1147, 1149, 955, 1195, and 353, wherein the modified oligonucleotide comprises\n a gap segment consisting of ten linked deoxynucleosides; a 5\u2032 wing segment consisting of three linked nucleosides; and a 3\u2032 wing segment consisting of three linked nucleosides; wherein the gap segment is positioned between the 5\u2032 wing segment and the 3\u2032 wing segment; wherein the 5\u2032 wing segment and the 3\u2032 wing segment comprise cEt sugars; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 90.0
- Lexical Diversity: 1.26923
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12478488', '14959714', '14149715', '14839580', '14701999']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7878274603156441
- 35 USC 102 Novelty (BERT): 0.5298196463251436
- Combined Prediction Score: 0.762026678916594
- Mean Citation Score: 352.086664
- Max Citation Score: 362.38525
- Similarity Product: 269.76153293326496

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test